DYAX
Last week, a few biotech companies made absolutely massive runs, while others had serious falls.
Published:
Last Updated:
Shire and Dyax announced Monday morning that former will acquire latter for almost $6 billion.
Published:
Last Updated:
A report on Wednesday from Janney Capital Markets has targeted several iotech bcompanies it believes are now grossly oversold.
Published:
Dyax announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending DX-2930.
Published:
The dog days of August have typically meant slow volumes, but it did not keep technology and financial services insiders from unloading shares.
Published:
Dyax announced on Tuesday that the FDA has granted a key breakthrough therapy designation for the investigation of DX-2930 for hereditary angioedema .
Published:
Monday's top analyst upgrades, downgrades and initiations include AOL, Cisco Systems, Etsy, GoDaddy, MannKind, Virtu Financial, Caterpillar and Nokia.
Published:
The newest hot stock in biotechnology is now giving everyone the chance to get a piece of it via an offering of 7 million shares of its common stock.
Published:
Last Updated:
So far, analysts have not backed off their bullish views of Dyax. In fact, many analysts boosted their price targets remarkably on the news.
Published:
Wednesday's top analyst upgrades and downgrades include Alibaba, Altera, Dyax, Hewlett-Packard, Kinder Morgan, Michael Kors, Staples and Twitter.
Published:
Dyax is almost certain to dominate the biotech news flow on Wednesday, after it announced positive trial data on Tuesday evening.
Published:
A new research report from the analysts at Merrill Lynch includes some timely additions to the firm's SMID-Cap Alpha list.
Published:
Last Updated:
In a new report from RBC, while they think the selling and profit taking in biotechs could go on, they also hold fast that industry fundamentals are still very positive.
Published:
Here are five stocks on the Merrill Lynch SMID-Cap Alpha list that have some big news and events that may be right around the corner. All are rated Buy at Merrill Lynch.
Published:
A new research note from Cowen focuses on health care companies that have released earnings and offer investors reasons to own the stocks.
Published: